Beta-blockade With Landiolol in Out-of-hospital Cardiac Arrest (Beta-Arrest)

Medical University of Vienna

Status and phase: Enrolling; Phase 2; Phase 1

Conditions: Cardiac Arrest

Treatments: Drug: Sodium Chloride (NaCl) 0.9%; Drug: Landiolol

Study type: Interventional

Funder types: Other

Identifiers

NCT05554978

Beta Blockade Cardiac Arrest

Details and patient eligibility

About

This study investigates the efficacy of landiolol versus placebo in patients with out-of-hospital cardiac arrest (OHCA) and refractory ventricular fibrillation (electrical storm).

Full description

The use of beta-blockers in OHCA patients with refractory VF could potentially reverse the unwanted beta-1-mediated effects of endogenous and exogenous epinephrine (proarrhythmic effect), which could in turn lead to a shorter time until return of spontaneous circulation (ROSC).

This is a prospective, double-blind, randomized placebo-controlled pilot trial. The investigators consider this a pilot trial, as this is the first prospective trial evaluating the use of beta-blockade in cardiac arrest.

Enrollment: 32 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• OHCA , >/=18 years of age
• 3 or more shockable rhythms (VF or pVT) and last rhythm shockable

Exclusion criteria

• Age > 85a
• Severe head trauma or acute active bleeding
• Known allergy or insensitivity to landiolol or another beta-blocker

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

32 participants in 2 patient groups, including a placebo group

Landiolol

Experimental group

Description:

initial dose: 20mg target dose: repeated dose (20mg) possible, max. 40mg (total)

Treatment:

Drug: Landiolol

Placebo

Placebo Comparator group

Description:

Sodium Chlorid 0,9%

Treatment:

Drug: Sodium Chloride (NaCl) 0.9%